


## Tetrac

## Chemical Properties

CAS No. :	67-30-1
Formula:	C <sub>14</sub> H <sub>8</sub> I <sub>4</sub> O <sub>4</sub>
Molecular Weight:	747.83
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Tetrac (Tetraiodothyroacetic acid) is a derivative of L-thyroxine (T4), a thyroxine integrin receptor antagonist. Tetrac induces antiproliferation by blocking EGFR-mediated cell signaling in colorectal cancer cells. Tetrac blocks the effects of T4 and 3,5,3'-triiodo-L-thyronine (T3) on the cell-surface thyroxine integrin $\alpha\beta 3$ receptors. Tetra has anti-angiogenic, anti-tumor activity and pro-apoptotic activity.
Targets(IC50)	Apoptosis, EGFR, Endogenous Metabolite, Integrin
In vitro	Tetrac (0.01-1 $\mu$ M; 2-6 d) induces anti-proliferation in HT-29 and HCT116 cells with different K-RAS status, inhibits ERK1/2 activation (0.1 $\mu$ M; 30 min), and modulates expression of CCND1, c-Myc, CASP2, and THBS1 (0.1 $\mu$ M; 24 h), as demonstrated by cell proliferation assays in HT-29 and HCT116 cells[3].
In vivo	Tetrac (35 $\mu$ g/day; p.o.; for 40 days; Wild-type male Balb/C mice inoculated with 102B16F10 or B16LS9 cells) delayed the onset of ocular melanoma and reduced the S-100 and integrin staining levels. Tetrac can inhibit tumor inoculation, growth, and integrin expression in mice.[4]

## Solubility Information

Solubility	DMSO: 250 mg/mL (334.3 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	1.3372 mL	6.686 mL	13.372 mL
5 mM	0.2674 mL	1.3372 mL	2.6744 mL
10 mM	0.1337 mL	0.6686 mL	1.3372 mL
50 mM	0.0267 mL	0.1337 mL	0.2674 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

- Schmohl KA, et al. Tetrac as an anti-angiogenic agent in cancer. *Endocr Relat Cancer*. 2019;26(6):R287-R304.
- Davis PJ, et, al. Nongenomic Actions of Thyroid Hormone: the Integrin Component. *Physiol Rev*. 2020 Jun 25.
- Chin YT, et, al. Tetrac and NDAT Induce Anti-proliferation via Integrin  $\alpha\beta 3$  in Colorectal Cancers With Different K-RAS Status. *Front Endocrinol (Lausanne)*. 2019 Mar 12; 10:130.
- Ashur-Fabian O, et, al. Tetrac Delayed the Onset of Ocular Melanoma in an Orthotopic Mouse Model. *Front Endocrinol (Lausanne)*. 2019 Jan 8;9:775.
- Rajabi M, et, al. Synthesis of new analogs of tetraiodothyroacetic acid (tetrac) as novel angiogenesis inhibitors for treatment of cancer. *Bioorg Med Chem Lett*. 2018 Apr 15;28(7):1223-1227.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481